Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Ontario and Chicago, Illinois--(Newsfile Corp. - September 24, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated August 10, 2026 as directors through the next annual meeting. Shareholders also voted in favor of the appointment of PricewaterhouseCoopers LLP as the company's auditors and in favor of resolutions amending the c
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-09-24 5:30 PM EDT | Medexus Pharmaceuticals Inc.
OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)
New York and Rockville, Maryland--(Newsfile Corp. - September 24, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announce that the World Health Organization has approved the proprietary name 'Herlystic'™ was approved by the World Health Organization (WHO) as the brand name for OST-HER2. The nonproprietary name daznelimgene lisbac for the ingredients
2026-09-24 8:22 AM EDT | OS Therapies
TempraMed Expands Latin American Distribution Agreement with TEM and Receives Additional Commercial Order, Announces Private Placement
Highlights TempraMed and TEM Consulting International S.A. execute amendment expanding the distribution relationship beyond Panama to additional Latin American markets. The amended framework adds VIVI Med™ to the covered product portfolio, alongside VIVI Cap™ and VIVI Epi™. TempraMed received an additional commercial order from TEM, expected to be fulfilled by the end of September 2026. Initial extended-territ
Technology, Biotechnology, Pharmaceuticals, Health
2026-09-24 2:55 AM EDT | TempraMed Technologies Ltd.
Hemostemix Non Brokered Private Placement
Calgary, Alberta--(Newsfile Corp. - September 23, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is filing a Form 4B to obtain price protection for the closing of the third tranche of its previously announced non-brokered private placement of units (the "Offering"), as originally disclosed on June 17, 2026, to raise $1,000,000. Each Unit consists of one common share in the capital of the Company (a "Common Share") and
Biotechnology, Pharmaceuticals, Health
2026-09-23 4:10 PM EDT | Hemostemix Inc.
Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer, today announced that it will present at the Life Sciences Future 2026 Conference, taking place September 30 to October 1, 2026, at the Sheraton Valley Forge Hotel in King of Prussia, Pennsylvania. Robert Bitter
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-09-23 7:00 AM EDT | Phio Pharmaceuticals Corp.
TempraMed Announces Distribution Agreement with CenterWell Pharmacy(R), the Pharmacy Services Brand of Humana
Toronto, Ontario--(Newsfile Corp. - September 23, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce it has entered into a distribution agreement dated August 25, 2026 (the "Distribution Agreement") with CenterWell Pharmacy, Inc. ("CenterWell") the pharmacy services brand of Humana Inc, a m
Technology, Biotechnology, Pharmaceuticals, Health
2026-09-23 3:05 AM EDT | TempraMed Technologies Ltd.
DIMERx Secures Second NIH Award to Advance DMX-201 for Sickle Cell Disease
San Francisco, California--(Newsfile Corp. - September 22, 2026) - DIMERx, Inc., a clinical-stage biopharmaceutical company developing novel dimer-based therapeutics, today announced that it has received a Small Business Innovation Research (SBIR) award from the National Heart, Lung, and Blood Institute (NHLBI) to advance DMX-201 for sickle cell disease (SCD). DMX-201 has the potential to become a first-line therapy for acute chest syndrome (ACS), helping reduce acute respiratory distress, sh
Biotechnology, Pharmaceuticals, Health
2026-09-22 9:00 AM EDT | DIMERx INC.
Envoy Medical Announces New Patents, Further Expanding Global Patent Portfolio
White Bear Lake, Minnesota--(Newsfile Corp. - September 22, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the grant of two additional international patents, expanding its global intellectual property portfolio to 97 patents, consisting of 40 U.S. and 57 foreign patents. In addition, the Company has 26 pending foreign applications and 9 pending U.S. applications.
Biotechnology, Healthcare and Hospitals
2026-09-22 8:30 AM EDT | Envoy Medical, Inc.
BioMark Announces Participation in upcoming MSACL 2026 and BIOHorizon 2026 Life Sciences Conferences
Vancouver, British Columbia--(Newsfile Corp. - September 21, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies focused on the early detection of lung cancer through metabolomics, is pleased to announce today its participation in two upcoming life sciences events in Quebec during the week of October 4, 2026. The Company will participate in the 16th Annual Mass Spectrometry & Advances i
Technology, Biotechnology, Healthcare and Hospitals
2026-09-21 8:30 AM EDT | BioMark Diagnostics, Inc.
OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis
Recent U.K. MHRA Scientific Advice Meeting (SAM) that resulted in full alignment to initiate confirmatory Phase 3 trial in U.K. with existing Phase 2 drug product paved the way Conditional Marketing Authorisation Application (CMAA) submission in the coming weeks and Phase 3 trial initiation in mid Q4/'26 following Phase 2b drug product requalification MHRA's SAM participants' recommendation to Project Orbis U.K. leadership to take the glob
2026-09-21 6:30 AM EDT | OS Therapies
TempraMed Reports Record July Sales and Strong August Performance, with Year-to-Date Sales Already Exceeding Full-Year 2025 Revenue
Toronto, Ontario--(Newsfile Corp. - September 18, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to provide an interim sales update regarding its recent commercial performance. The Company reports that July 2026 sales reached approximately US$522,000, representing the highest monthly sales level in T
Technology, Biotechnology, Pharmaceuticals, Health
2026-09-18 4:45 PM EDT | TempraMed Technologies Ltd.
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance
Vancouver, British Columbia--(Newsfile Corp. - September 18, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announces that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that the shareholders' eq
Biotechnology, Pharmaceuticals
2026-09-18 4:45 PM EDT | InMed Pharmaceuticals
Correcting and Replacing: Theralase(R) Releases Q2 2026 Financial Statements
Toronto, Ontario--(Newsfile Corp. - September 18, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-09-18 7:00 AM EDT | Theralase Technologies Inc.
Marvel Biosciences Provides Update on Private Placement for up to $3.0 Million
Calgary, Alberta--(Newsfile Corp. - September 17, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") announced today that, further to its July 16, 2026, August 19, 2026 and September 9, 2026 press releases, it intends to complete a non‐brokered private placement offering (the "Offering") of units of the Company ("Units") at a price of $0.15 per Unit. The Offering will be for a minimum of 10,000,000 Units for gross procee
2026-09-17 5:05 PM EDT | Marvel Biosciences Corp.
Marvel Biosciences fait le point sur un placement privé pouvant atteindre 3 millions de dollars
Calgary, Alberta--(Newsfile Corp. - 17 septembre 2026) - Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) (« Marvel » ou la « Société ») a annoncé aujourd'hui que, à la suite de ses communiqués de presse des 16 juillet 2026, 19 août 2026 et 9 septembre 2026, elle entend réaliser un placement privé sans courtier (le « Placement ») d'unités de la Société (les « Unités »)
2026-09-17 5:05 PM EDT | Marvel Biosciences Corp.
OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program
New York and Rockville, Maryland--(Newsfile Corp. - September 17, 2026) - OS
2026-09-17 6:00 AM EDT | OS Therapies
Cashu Research Initiates Coverage on K2 Gold Corporation (KTO)
Vancouver, British Columbia--(Newsfile Corp. - September 16, 2026) - Cashu Research today initiated coverage on K2 Gold Corporation (TSXV: KTO) (OTCQX: KTGDF), focused on the company's 100%-owned Mojave Project in Inyo County, California. Read the full report: https://research.cashugroup.com/research-repo
Biotechnology, Mining and Metals, Precious Metals, Oil & Gas
2026-09-16 9:49 AM EDT | Cashu Group
Nextleaf Announces Leadership Transition and Strategic Review; Sam Kassem Appointed Interim CEO
Vancouver, British Columbia--(Newsfile Corp. - September 15, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf" or the "Company"), an innovation-driven Canadian cannabis processor, announces that Emma Andrews has stepped down as Chief Executive Officer, President and a director of the Company. The Board of Directors has appointed Sam Kassem, the Company's current Chief Financial Officer and a director of the Company, as Interim Chief Executive Officer
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2026-09-15 7:50 PM EDT | Nextleaf Solutions Ltd.
La Vie Health and Virotek Biosciences Partner to Advance the Next Generation of Precision Health
Ontario and Richmond Hill, Ontario--(Newsfile Corp. - September 15, 2026) - La Vie Health ("La Vie") and Virotek Biosciences ("Virotek") today announced a strategic collaboration to integrate advanced genomic insights into La Vie's broader physician-led preventative, precision and healthspan model. This partnership advances both companies' commitment to precision health, with Virotek adding a clinically contextualized genomic layer to La Vie's comprehensive precision-health prog
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-09-15 8:30 AM EDT | Virotek Biosciences Inc.
AquaBounty Announces Engagement of Colliers as Exclusive Agent for its Ohio Property
Harvard, Massachusetts--(Newsfile Corp. - September 15, 2026) - AquaBounty Technologies, Inc. (NASDAQ: AQB) ("AquaBounty," "we," "our" or the "Company") today announced that it has engaged Colliers as its exclusive real estate agent and advisor for its Pioneer, Ohio property as part of the Company's ongoing strategic review process. The Company previously announced that it was broadening its evaluation of strategic alternatives to maximize shareholder value. The Pioneer campus posses
Agriculture, Biotechnology, Food / Beverages
2026-09-15 8:15 AM EDT | AquaBounty Technologies, Inc.